RxSight, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $134.5M | $139.9M | $89.1M | $49.0M | $22.6M |
| Cost of revenue | $31.5M | $41.0M | $35.3M | $27.7M | $18.1M |
| Gross profit | $103.0M | $98.9M | $53.8M | $21.3M | $4.5M |
| Selling, general & administrative | $112.7M | $101.4M | $74.8M | $58.7M | $32.8M |
| Research and development | $38.5M | $34.4M | $29.1M | $26.0M | $24.5M |
| Operating expenses | $151.2M | $135.8M | $103.8M | $84.6M | $57.3M |
| Operating income | -$48.2M | -$36.9M | -$50.1M | -$63.3M | -$52.8M |
| Interest expense | $19,000 | $21,000 | $3.3M | $4.9M | $3.7M |
| Pretax income | -$38.9M | -$27.4M | -$48.6M | -$66.7M | -$48.7M |
| Income tax expense | $66,000 | $50,000 | $20,000 | $9,000 | $8,000 |
| Net income | -$38.9M | -$27.5M | -$48.6M | -$66.8M | -$48.7M |
| Balance Sheet | |||||
| Cash and equivalents | $19.9M | $16.7M | $9.7M | $11.8M | $24.4M |
| Current assets | $287.5M | $293.8M | $168.4M | $134.6M | $176.3M |
| Total assets | $311.8M | $318.6M | $182.6M | $150.2M | $192.7M |
| Current liabilities | $26.3M | $25.9M | $20.9M | $17.2M | $11.1M |
| Total liabilities | $36.1M | $37.3M | $22.2M | $60.3M | $54.5M |
| Total debt | — | — | — | $40.0M | $40.0M |
| Stockholders' equity | $275.7M | $281.2M | $160.4M | $89.9M | $138.2M |
| Cash Flow Statement | |||||
| Cash from operations | -$15.5M | -$16.9M | -$41.6M | -$58.9M | -$44.7M |
| Depreciation and amortization | $3.3M | $3.6M | $4.1M | $3.9M | $4.0M |
| Stock-based compensation | $31.6M | $24.6M | $15.7M | $11.4M | $7.6M |
| Capital expenditure | $3.8M | $5.4M | $4.8M | $2.4M | $1.9M |
| Free cash flow | -$19.3M | -$22.4M | -$46.4M | -$61.2M | -$46.6M |
Shares outstanding 41.4M · Free float 69.0%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.